Work

Fab-targeted gold nanoparticle probes outperform fc-targeted and dual-epitope formats in nanoparticle tracking analysis of a bivalent model analyte: a proof-of-concept study using human IgG

Year: 2026
Type: article
Abstract: Introduction Nanoparticle aggregation assays read out by bulk optical measurement are limited in sensitivity because, at low analyte concentrations, only a small fraction of particles associate. As a methodological proof of concept, we asked whether the epitope that a capture antibody recognises on a multivalent analyte governs the performance of gold nanoparticle (AuNP) aggregation assays read out by nanoparticle tracking analysis (NTA). Human immunoglobulin G (IgG) was used purely as a bivalent model scaffold, not as a clinical target. Methods AuNPs were functionalised through a streptavidin bridge with biotinylated antibodies against either the Fab or the Fc region of IgG, and the two probes were tested individually and as a one-to-one mixture across 19.9–199.4 fg/mL (0.13–1.33 fM) of antigen, with association followed by ultraviolet–visible (UV–Vis) spectroscopy and by NTA. Results Both methods ranked the three formats identically. The Fab-targeted probe was the only format with a monotonic, linear response (R 2 = 0.953), giving an NTA limit of detection of 65.1 fg/mL (0.43 fM) within a 35-minute assay, approximately 6.7 × 104-fold below its UV–Vis limit (4.33 ng/mL). Discussion Because the calibrated range spans one order of magnitude and the limit of quantification (197 fg/mL; 1.31 fM) lies at its upper end, the assay is best regarded as detecting and semi-quantitatively ranking antigen rather than quantifying it. The mixed probe gave the largest signal but a stepwise response suited to qualitative screening. The Fc-targeted probe did not titrate; because this preparation was already partially aggregated before antigen addition, its failure cannot be attributed to epitope choice alone. Antibody-free and non-target-antigen controls remained at baseline, but the magnitude of the NTA response exceeds what one-to-one antigen bridging of particles could produce, so the aggregation index is treated as an empirical, antigen-specific indicator whose amplification mechanism remains to be resolved. All measurements were made in dilute buffer, so matrix tolerance was not tested. Validation in serum, comparison with a reference immunoassay, and extension to genuinely low-abundance multivalent biomarkers are required before any diagnostic use is considered.
Language: English
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236630034
FWCI:
Cites: 34
Cited by:
Related to: 10
Parts: 1